Contineum Therapeutics (CTNM) Equity Average: 2024-2025
Historic Equity Average for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $175.9 million.
- Contineum Therapeutics' Equity Average fell 17.74% to $175.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.9 million, marking a year-over-year decrease of 17.74%. This contributed to the annual value of $65.1 million for FY2024, which is N/A change from last year.
- As of Q3 2025, Contineum Therapeutics' Equity Average stood at $175.9 million, which was down 1.21% from $178.1 million recorded in Q2 2025.
- Over the past 5 years, Contineum Therapeutics' Equity Average peaked at $213.9 million during Q3 2024, and registered a low of -$71.8 million during Q1 2024.
- Over the past 2 years, Contineum Therapeutics' median Equity Average value was $178.1 million (recorded in 2025), while the average stood at $137.5 million.
- Examining YoY changes over the last 5 years, Contineum Therapeutics' Equity Average showed a top increase of 366.66% in 2025 and a maximum decrease of 17.74% in 2025.
- Quarterly analysis of 2 years shows Contineum Therapeutics' Equity Average stood at $204.1 million in 2024, then declined by 17.74% to $175.9 million in 2025.
- Its Equity Average was $175.9 million in Q3 2025, compared to $178.1 million in Q2 2025 and $191.4 million in Q1 2025.